Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May 28;7(9):1168-83.
doi: 10.4254/wjh.v7.i9.1168.

Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives

Jan Erik Slotta  1 , Otto Kollmar  1 , Volker Ellenrieder  1 , B Michael Ghadimi  1 , Kia Homayounfar  1
Affiliations
Review

Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives

Jan Erik Slotta et al. World J Hepatol. .

Abstract

Hepatocellular carcinoma (HCC) is the most common liver-derived malignancy with a high fatality rate. Risk factors for the development of HCC have been identified and are clearly described. However, due to the lack of tumor-specific symptoms, HCC are diagnosed at progressed tumor stages in most patients, and thus curative therapeutic options are limited. The focus of this review is on surgical therapeutic options which can be offered to patients with HCC with special regard to recent findings, not exclusively focused on surgical therapy, but also to other treatment modalities. Further, potential promising future perspectives for the treatment of HCC are discussed.

Keywords: Extended indications; Hepatocellular carcinoma; Interventional therapy; Multimodal treatment; Surgical therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart displaying the recommended treatment according to the barcelona clinic liver cancer tumor stage (adapted from European Association for the Study of the Liver-European Organization for Research and Treatment of Cancer Clinical Practice Guidelines). CP: Child-Pugh; HCC: Hepatocellular carcinoma; PST: Performance status; Cis: Carcinoma in situ; LTx: Liver transplantation; RFA: Radiofrequency ablation; PEI: Percutaneous ethanol injection; TACE: Transarterial chemoembolization.
See this image and copyright information in PMC

References

    1. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol. 2003;39:1076–1084. - PubMed
    1. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2–S6. - PMC - PubMed
    1. Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19–37. - PMC - PubMed
    1. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Available from: http://www.seer.cancer.gov/faststats.
    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. - PubMed

LinkOut - more resources